DK0804237T3 - Humaniserede antistoffer mod leukocyt-adhæsionsmolekyle VLA-4 - Google Patents

Humaniserede antistoffer mod leukocyt-adhæsionsmolekyle VLA-4

Info

Publication number
DK0804237T3
DK0804237T3 DK95908741T DK95908741T DK0804237T3 DK 0804237 T3 DK0804237 T3 DK 0804237T3 DK 95908741 T DK95908741 T DK 95908741T DK 95908741 T DK95908741 T DK 95908741T DK 0804237 T3 DK0804237 T3 DK 0804237T3
Authority
DK
Denmark
Prior art keywords
humanized antibodies
adhesion molecule
leukocyte adhesion
molecule vla
vla
Prior art date
Application number
DK95908741T
Other languages
Danish (da)
English (en)
Inventor
Jose Saldanha
Theodore A Yednock
Mary M Bendig
Olivier J Leger
Tarran S Jones
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Application granted granted Critical
Publication of DK0804237T3 publication Critical patent/DK0804237T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK95908741T 1994-01-25 1995-01-25 Humaniserede antistoffer mod leukocyt-adhæsionsmolekyle VLA-4 DK0804237T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18626994A 1994-01-25 1994-01-25

Publications (1)

Publication Number Publication Date
DK0804237T3 true DK0804237T3 (da) 2006-10-16

Family

ID=22684288

Family Applications (2)

Application Number Title Priority Date Filing Date
DK95908741T DK0804237T3 (da) 1994-01-25 1995-01-25 Humaniserede antistoffer mod leukocyt-adhæsionsmolekyle VLA-4
DK06013916.9T DK1759709T3 (da) 1994-01-25 1995-01-25 Humaniserede antistoffer mod leukocytadhæsionsmolekyle VLA-4

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK06013916.9T DK1759709T3 (da) 1994-01-25 1995-01-25 Humaniserede antistoffer mod leukocytadhæsionsmolekyle VLA-4

Country Status (21)

Country Link
EP (2) EP0804237B8 (pl)
JP (5) JP4115517B2 (pl)
KR (1) KR100367948B1 (pl)
CN (1) CN1211123C (pl)
AT (1) ATE333895T1 (pl)
AU (1) AU703152B2 (pl)
CA (1) CA2182013C (pl)
DE (2) DE122006000043I1 (pl)
DK (2) DK0804237T3 (pl)
ES (2) ES2424292T3 (pl)
FI (1) FI117509B (pl)
FR (1) FR06C0024I2 (pl)
HU (1) HU220799B1 (pl)
LU (1) LU91271I2 (pl)
MX (1) MX9602971A (pl)
NL (1) NL300238I2 (pl)
NO (3) NO319867B1 (pl)
NZ (1) NZ279730A (pl)
PL (1) PL181827B1 (pl)
PT (1) PT804237E (pl)
WO (1) WO1995019790A1 (pl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
NZ261259A (en) 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
JP3593343B2 (ja) * 1993-02-09 2004-11-24 バイオジェン インコーポレイテッド インシュリン依存型糖尿病の治療
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
WO1998051345A2 (en) * 1997-05-09 1998-11-19 The John P. Robarts Research Institute Method for dislodging infiltrated leukocytes from a tissue
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
AU757873B2 (en) * 1998-09-14 2003-03-06 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
PL198975B1 (pl) 1999-04-22 2008-08-29 Biogen Idec Inc Zastosowanie kompozycji zawierającej homolog przeciwciała, który jest antagonistą interakcji między integryną niosącą podjednostkę alfa 4 a jej ligandem
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
HK1043320A1 (zh) 1999-06-01 2002-09-13 Biogen, Inc. Vla-1的一种阻塞性单系抗体，以及其治疗炎性失调的功用
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP2003517023A (ja) * 1999-12-16 2003-05-20 バイオジェン インコーポレイテッド 中枢神経系の虚血性損傷または出血性損傷を、抗α４インテグリンアンタゴニストを用いて処置する方法
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
UA83791C2 (ru) 2001-04-13 2008-08-26 Байоджен Айдек Ма Инк. Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
SI1485127T1 (sl) 2002-02-25 2011-09-30 Elan Pharm Inc Dajanje aktivne snovi za zdravljenje vnetja
JP2005535572A (ja) * 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド 組換え抗インターロイキン−９抗体
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
CN100432105C (zh) * 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
EP1700850B1 (en) 2003-12-22 2015-07-15 Ajinomoto Co., Inc. Phenylalanine derivative
JP2008520717A (ja) * 2004-11-19 2008-06-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド 多発性硬化症についての処置
JP2009515552A (ja) * 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリン反応性ヒト化免疫グロブリン
BRPI0712607A8 (pt) 2006-05-25 2019-06-04 Biogen Idec Inc métodos de tratamento de acidente vascular cerebral
EP2510941A3 (en) 2007-02-20 2013-01-23 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
NZ595526A (en) * 2007-06-14 2013-03-28 Biogen Idec Inc Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
EP2221325B1 (en) 2007-12-13 2014-04-16 Tokuyama Corporation Photochromic curable composition
BRPI0911652A2 (pt) 2008-04-11 2015-08-04 Merrimack Pharmaceuticals Inc Ligantes de albumina sérica humana e seus conjugados
WO2010107752A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
US20120258093A1 (en) 2009-08-20 2012-10-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
EA201291065A1 (ru) 2010-04-16 2013-03-29 Байоджен Айдек Ма Инк. Антитела против vla-4
TWI907924B (zh) 2011-05-02 2025-12-11 日商武田藥品工業股份有限公司 抗-α4β7抗體之調配物
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
ES2732243T3 (es) 2012-02-16 2019-11-21 Santarus Inc Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
US20190225694A1 (en) 2016-06-28 2019-07-25 Zaklady Farmaceutyczne Polpharma Sa Recombinant production of monoclonal antibodies
EP3541413A2 (en) 2016-11-21 2019-09-25 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
EP3583126B1 (en) * 2017-02-17 2025-08-27 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
US12043845B2 (en) 2017-06-08 2024-07-23 Polpharma Biologics S.A. Methods of cell culture
JP7457661B2 (ja) 2018-06-04 2024-03-28 バイオジェン・エムエイ・インコーポレイテッド 低減したエフェクター機能を有する抗ｖｌａ－４抗体
US20240301512A1 (en) 2021-01-29 2024-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL95501A (en) * 1989-09-01 1997-04-15 Hutchinson Fred Cancer Res Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
CA2129637C (en) * 1992-02-12 1999-05-04 Roy R. Lobb Treatment for inflammatory bowel disease
NZ261259A (en) * 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
AUPP647298A0 (en) 1998-10-13 1998-11-05 Keystone Retaining Wall Systems, Inc. Retaining wall block

Also Published As

Publication number Publication date
AU1696095A (en) 1995-08-08
EP1759709B1 (en) 2013-02-27
HU220799B1 (hu) 2002-05-28
ES2424292T3 (es) 2013-09-30
WO1995019790A1 (en) 1995-07-27
KR970700513A (ko) 1997-02-12
JP2013173738A (ja) 2013-09-05
JP2009235078A (ja) 2009-10-15
FR06C0024I2 (fr) 2009-01-02
NO2006008I1 (no) 2006-08-07
EP0804237A4 (en) 2003-04-16
AU703152B2 (en) 1999-03-18
PL315634A1 (en) 1996-11-25
MX9602971A (es) 1998-01-31
DE69535133D1 (de) 2006-09-07
PT804237E (pt) 2006-10-31
HUT75129A (en) 1997-04-28
NL300238I1 (pl) 2006-10-02
ATE333895T1 (de) 2006-08-15
NZ279730A (en) 1998-04-27
JP2006045237A (ja) 2006-02-16
HU9602019D0 (en) 1996-09-30
NO963097L (no) 1996-09-24
DE122006000043I1 (de) 2007-02-15
ES2270425T3 (es) 2007-04-01
EP1759709A1 (en) 2007-03-07
CA2182013C (en) 2007-07-17
NO319867B1 (no) 2005-09-26
NL300238I2 (nl) 2007-05-01
CN1211123C (zh) 2005-07-20
FI117509B (fi) 2006-11-15
FI962958L (fi) 1996-09-24
JP2013165718A (ja) 2013-08-29
LU91271I2 (fr) 2006-10-02
DK1759709T3 (da) 2013-06-10
FR06C0024I1 (pl) 2006-10-13
NO963097D0 (no) 1996-07-24
JP5487382B2 (ja) 2014-05-07
NO2006008I2 (no) 2009-06-15
EP0804237B1 (en) 2006-07-26
JP4115517B2 (ja) 2008-07-09
NO2017040I1 (no) 2017-08-01
NO2017040I2 (no) 2018-08-28
EP0804237B8 (en) 2006-11-08
CA2182013A1 (en) 1995-07-27
EP0804237A1 (en) 1997-11-05
JPH09508272A (ja) 1997-08-26
FI962958A0 (fi) 1996-07-24
CN1140413A (zh) 1997-01-15
PL181827B1 (pl) 2001-09-28
DE69535133T2 (de) 2008-08-21
KR100367948B1 (ko) 2003-07-12

Similar Documents

Publication Publication Date Title
DK1759709T3 (da) Humaniserede antistoffer mod leukocytadhæsionsmolekyle VLA-4
NO961151D0 (no) Antistoffer mot CD40
DE69636748D1 (de) Bispezifischer antikörper zur effektiven behandlung von b-zell lymphomen und zellinien
DE69531679D1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
ATE218387T1 (de) Antikörperreinigung
EP0728215A4 (en) METHOD FOR BINDING MATERIAL TO THE -g (b) AMYLOID PEPTIDE
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
MY154009A (en) Anti-alpha v beta 6 antibodies
DK1414861T3 (da) Humaniserede antistoffer mod ICAM-1, fremstilling og anvendelse heraf
DE59209129D1 (de) Verwendung von Antikörper enthaltenden Präparationen zur Immunsuppression
EP1112085A4 (en) ANTI-THROMBOTIC AGENT AND HUMANIZED MONOCLONAL ANTIBODY AGAINST VON-WILLEBRAND FACTOR
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
DE69103214D1 (de) Verfahren zur Reinigung von Glycin.
ATE222927T1 (de) Monoklonaler antikörper gegen den tumorzytotoxischen faktor ii (tcf-ii)
DE69601154D1 (de) Zubereitungen für die Behandlung von Hepatitis C